Glioblastoma is the most aggressive and lethal form of brain cancer in adults. Despite decades of research and advances in surgery, chemotherapy, and radiation, median survival remains just 14 to 16 months after diagnosis, with fewer than 5% of patients surviving five years. Now, a newly published NIH-funded study is upending a long-held assumption about this disease — and offering a potentially unexpected therapeutic lead.
Researchers have found that testosterone, the primary male sex hormone, may actually suppress glioblastoma growth rather than fuel it. The findings, published in May 2026, suggest that losing androgen hormones like testosterone creates a biological cascade that allows tumors to evade the immune system and grow unchecked.
Why Researchers Suspected Testosterone Was the Problem
Men develop glioblastoma at slightly higher rates than women, a disparity that led scientists to suspect sex hormones might play a role in driving tumor growth. For years, testosterone was viewed as a potential villain — a hormone that could be fueling the male-biased incidence of this cancer.
“Many researchers have suspected that these hormones are part of the problem,” the study authors noted. But a critical gap existed: no one had rigorously examined what testosterone actually does inside the brain’s unique immunological environment.
The new NIH-funded study set out to fill that gap — and what researchers found was the opposite of what many had predicted.
How the Study Was Designed
The research team took a two-pronged approach combining preclinical mouse models with large-scale clinical data analysis.
In laboratory experiments, researchers used mouse models of glioblastoma and systematically reduced androgen levels to observe what happened to tumor growth. Simultaneously, the team analyzed data from over 1,300 men diagnosed with glioblastoma through the NIH’s National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database — one of the most comprehensive cancer registries in the United States.
This dual design allowed researchers to study both the biological mechanism driving the effect and whether a clinical signal could be detected in real-world patient data.
The Surprising Finding: Androgen Loss Accelerates Tumor Growth
When researchers reduced androgen levels in male mice with glioblastoma, tumor growth did not slow down — it accelerated. The results pointed to a biological mechanism that few had considered: testosterone may be protecting the brain’s immune environment against tumor invasion.
Here is what the researchers found happening inside the body:
- Androgen loss activates the stress axis. When testosterone drops, the hypothalamic-pituitary-adrenal (HPA) axis — the body’s central stress-response system — becomes activated.
- Stress hormones flood the brain. HPA axis activation triggers a surge in cortisol and other stress hormones.
- The brain becomes immunosuppressed. These stress hormones create an immunosuppressive environment within the central nervous system, effectively quieting the immune cells that would normally target tumor cells.
- Tumors escape immune surveillance. With fewer immune cells reaching the tumor, cancer cells can proliferate with far less resistance.
The researchers also found that tumor-induced inflammation in the hypothalamus — the brain region that governs the HPA axis — likely triggers this cascade in androgen-deficient mice, creating a self-reinforcing loop that accelerates tumor progression.
What the Clinical Data Showed
The findings from mouse models were striking enough, but the clinical data added a powerful human dimension to the story.
Among the more than 1,300 men with glioblastoma in the SEER database, those who were receiving testosterone supplementation had a 38% lower risk of death compared to men who were not taking supplements. The effect appeared to be sex-specific — no similar protective pattern was observed in female mice exposed to testosterone.
Researchers are careful to note that this clinical association “does not establish a causal relationship.” Men who take testosterone supplements may differ from those who don’t in ways that could influence survival outcomes — including overall health status, access to care, or other treatments received. Rigorous clinical trials will be needed to determine whether the relationship is truly causal.
What This Could Mean for Glioblastoma Treatment
If confirmed through clinical trials, these findings could reshape how oncologists approach glioblastoma — particularly for male patients.
Perhaps most critically, the research raises an important caution about a common cancer treatment strategy: androgen deprivation therapy. Widely used in prostate cancer treatment to slow hormone-dependent tumor growth, androgen deprivation may inadvertently worsen outcomes in male glioblastoma patients by triggering the same immunosuppressive cascade the researchers identified in their models.
“These findings may warrant exploration of the hormones as glioblastoma treatment,” the research team noted, calling for further investigation into whether testosterone supplementation — or protecting the HPA axis pathway — could serve as an adjunct therapy for this devastating cancer.
The research also highlights a broader principle gaining traction in oncology: the immune environment within the brain plays a decisive role in whether tumors progress or are held in check. Therapies that preserve or enhance immune cell access to tumors — rather than broadly suppressing the immune system — may offer new avenues for treating glioblastoma.
Important Caveats to Keep in Mind
As promising as these results are, several important limitations should temper expectations in the near term.
- Animal models don’t always translate to humans. Mouse models of glioblastoma have historically been poor predictors of what works in human clinical trials. The brain biology of mice and humans differs in important ways.
- The SEER data is observational. While the 38% lower risk of death is a compelling signal, it cannot rule out confounding factors. Men who use testosterone supplements may be healthier overall, more engaged with medical care, or receiving other interventions that affect survival.
- No clinical trials exist yet. Translating this finding into an approved therapy will require rigorous randomized controlled trials, which take years to design, conduct, and analyze.
- Testosterone therapy carries its own risks. Testosterone supplementation is not benign — it carries risks including cardiovascular effects, polycythemia, and potential impact on other hormone-sensitive cancers. It should only be used under close medical supervision.
What Comes Next
The research team is calling for follow-up studies to explore several key questions: Can protecting the HPA axis — or supplementing androgens — meaningfully slow glioblastoma progression in humans? Does the timing of testosterone levels relative to diagnosis matter? And could targeting the stress-hormone immunosuppression pathway offer a new class of brain cancer treatments?
Studies examining whether androgen deprivation therapy should be reconsidered for male glioblastoma patients are also likely to follow.
For patients and families navigating a glioblastoma diagnosis today, the study is a reminder that the science of this disease is still evolving — and that some long-held assumptions may be ripe for revision. Consult your oncology team about any emerging research and whether participation in a clinical trial may be appropriate for your situation.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.